{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T22:35:03Z","timestamp":1695162903197},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2004,8,27]],"date-time":"2004-08-27T00:00:00Z","timestamp":1093564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s00432-004-0598-z","type":"journal-article","created":{"date-parts":[[2004,8,26]],"date-time":"2004-08-26T15:53:48Z","timestamp":1093535628000},"page":"741-744","source":"Crossref","is-referenced-by-count":4,"title":["Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers"],"prefix":"10.1007","volume":"130","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,8,27]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.2001.6151","volume":"81","author":"Bolis","year":"2001","unstructured":"Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F (2001) Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81:3?9","journal-title":"Gynecol Oncol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/gyno.2001.6552","volume":"85","author":"Covens","year":"2002","unstructured":"Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M (2002) Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage III, III, or IV epithelial ovarian cancer. Gynecol Oncol 85:71?80","journal-title":"Gynecol Oncol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2002.20.5.1238","volume":"20","author":"Dizon","year":"2002","unstructured":"Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR (2002) Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20:1238?1247","journal-title":"J Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.1994.12.11.2317","volume":"12","author":"Goldberg","year":"1994","unstructured":"Goldberg GL, Gibbon DG, Smith HO, DeVictoria C, Runowicz CD, Burns ER (1994) Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 12:2317?2320","journal-title":"J Clin Oncol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.1998.16.7.2426","volume":"16","author":"Gore","year":"1998","unstructured":"Gore M, Mainwaring P, A?Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 16:2426?2434","journal-title":"J Clin Oncol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/gyno.2001.6364","volume":"83","author":"Gronlund","year":"2001","unstructured":"Gronlund B, Hogdall C, Hansen HH, Engelholm SA (2001) Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 83:128?134","journal-title":"Gynecol Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.1997.15.1.193","volume":"15","author":"Jakobsen","year":"1997","unstructured":"Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, Nielsen K, Sandberg E, Stroeyer I (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15:193?198","journal-title":"J Clin Oncol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","volume":"10","author":"Jodrell","year":"1992","unstructured":"Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520?528","journal-title":"J Clin Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/gyno.2000.5923","volume":"78","author":"Joly","year":"2000","unstructured":"Joly F, Heron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhomme C, Mace-Lesec?h J, Crouet H (2000) High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol 78:361?368","journal-title":"Gynecol Oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","volume":"5","author":"Markman","year":"2000","unstructured":"Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5:26?35","journal-title":"Oncologist"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1006\/gyno.1997.4708","volume":"65","author":"Markman","year":"1997","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1997) Continued chemosensitivity to cisplatin\/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 65:434?436","journal-title":"Gynecol Oncol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","volume":"13","author":"McGuire","year":"1995","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13:1589?1599","journal-title":"J Clin Oncol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194?3200","journal-title":"J Clin Oncol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1200\/JCO.1998.16.4.1494","volume":"16","author":"Rose","year":"1998","unstructured":"Rose PG, Fusco N, Fluellen L, Rodriguez M (1998) Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 16:1494?1497","journal-title":"J Clin Oncol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"The","year":"2003","unstructured":"The ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361:2099?2106","journal-title":"Lancet"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","volume":"360","author":"The","year":"2002","unstructured":"The International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505?515","journal-title":"Lancet"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-004-0598-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-004-0598-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-004-0598-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:37:09Z","timestamp":1559068629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-004-0598-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,27]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s00432-004-0598-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,27]]}}}